Gastroesophageal Reflux Disease in 2023: When to Operate and Current Endoscopic Options for Antireflux Therapy

Anuj Shah, Min P. Kim

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Gastroesophageal reflux disease (GERD) is among the most prevalent diseases in the United States. Mainstay therapy is lifestyle modification and medical therapy. If patients have GERD despite medical therapy, appropriate testing should be performed to determine if surgical or endoscopic therapy will provide improvement in their symptoms. Gold standard therapy is a minimally invasive fundoplication. Patients with body mass index <35, small or no hiatal hernia, normal motility, and pathologic GERD should consider magnetic sphincter augmentation. If a patient is not interested in either fundoplication or MSA, they should consider endoscopic treatment with either STRETTA or Transoral Incisionless fundoplication 2.0. A meta-analysis by Gong and colleagues showed that endoscopic treatments are better compared with medical therapy but are worse than surgical therapy.

Original languageEnglish (US)
Pages (from-to)125-134
Number of pages10
JournalThoracic Surgery Clinics
Volume33
Issue number2
DOIs
StatePublished - May 1 2023

Keywords

  • RFA
  • Radiofrequency ablation
  • TIF
  • Transoral incisionless fundoplication
  • Fundoplication
  • Humans
  • Gastroesophageal Reflux/diagnosis
  • Hernia, Hiatal/surgery
  • Quality of Life
  • Treatment Outcome
  • Laparoscopy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Gastroesophageal Reflux Disease in 2023: When to Operate and Current Endoscopic Options for Antireflux Therapy'. Together they form a unique fingerprint.

Cite this